SOSV

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Samphire Neuroscience is a neurotechnology company based in London, England, founded in 2021. The company focuses on women's health and lifestyle enhancement through innovative solutions. Its primary product is a headband device that employs non-invasive electrical neuromodulation to stimulate specific areas of the brain. This technology aims to alleviate symptoms commonly associated with menstrual cycles, including pain, fatigue, and mood disturbances, thereby improving the overall well-being of women.

Ria Health is a telehealth provider focused on treating alcohol use disorders through a mobile platform. Founded in 2013 and based in San Francisco, California, the company connects users with addiction specialists for personalized support and guidance. Ria Health employs evidence-based protocols, including medication-assisted treatment, harm reduction, and cognitive behavioral therapy, to assist heavy drinkers seeking to reduce or stop their alcohol consumption. The Ria app facilitates secure, HIPAA-compliant interactions, allowing for video and phone consultations, breathalyzer measurements, and progress tracking. By offering a private and convenient treatment option, Ria Health aims to address the significant gap in care for individuals struggling with alcohol-related issues, ensuring effective and affordable support that aligns with payer objectives.

Pannex Therapeutics is a scientifically-based pharmaceutical company that develops new drugs to treat chronic musculoskeletal pain. was founded in 2020.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

VemiCo is a biotechnology company focused on extending healthy living by addressing the aging process. It utilizes artificial intelligence and synthetic biology to identify and develop promising molecules derived from gut microbial DNA. This innovative approach allows medical professionals to leverage the benefits of microbiomes, promoting gut health and enhancing overall well-being.

Valanx Biotech GmbH, founded in 2017 and based in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company focuses on creating SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with therapeutic agents to produce antibody-drug conjugates for cancer treatment. This technology also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Valanx Biotech offers bioanalytics and mass spectrometry services to meet specific client needs, enhancing the efficiency and effectiveness of protein-drug conjugate development.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

Samphire Neuroscience is a neurotechnology company based in London, England, founded in 2021. The company focuses on women's health and lifestyle enhancement through innovative solutions. Its primary product is a headband device that employs non-invasive electrical neuromodulation to stimulate specific areas of the brain. This technology aims to alleviate symptoms commonly associated with menstrual cycles, including pain, fatigue, and mood disturbances, thereby improving the overall well-being of women.

Solving gout using engineered probiotics

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company specializes in developing innovative healthcare devices aimed at improving the weaning process for mechanically ventilated patients. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, which helps mitigate diaphragm dysfunction often caused by prolonged mechanical ventilation. This technology enables patients to transition off ventilators more quickly and safely, addressing a critical challenge in critical care settings.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases, particularly hyperkalemia, which involves high potassium levels. The company operates a wearable platform that delivers accurate and real-time potassium measurements through interstitial fluid from the skin, providing data closely correlated to blood levels. This innovation is crucial for heart and kidney care, as it enables clinicians and patients to monitor potassium levels effectively. By facilitating timely and informed decision-making regarding medications, diet, and treatment options, Proton Intelligence aims to enhance health outcomes and improve the quality of life for individuals living with chronic conditions.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases, particularly hyperkalemia, which involves high potassium levels. The company operates a wearable platform that delivers accurate and real-time potassium measurements through interstitial fluid from the skin, providing data closely correlated to blood levels. This innovation is crucial for heart and kidney care, as it enables clinicians and patients to monitor potassium levels effectively. By facilitating timely and informed decision-making regarding medications, diet, and treatment options, Proton Intelligence aims to enhance health outcomes and improve the quality of life for individuals living with chronic conditions.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

Tru, Inc. is a manufacturer of functional beverages designed to enhance energy, focus, and recovery for athletes and active individuals. Founded in 2015 and based in Natick, Massachusetts, the company produces energy shots infused with vitamins, electrolytes, and antioxidants. These products come in a variety of flavors, including electric mango, nootropic thunder, sour strawberry, recovery berry, and pineapple express, marketed under the brands Try Energy, Tru Focus, Tru Power, and Tru Rescue. Tru aims to support a healthy and active lifestyle by offering naturally formulated, non-GMO beverages that promote overall well-being and performance. The company sells its products through its online portal, making them accessible to a wider audience.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

Pannex Therapeutics is a scientifically-based pharmaceutical company that develops new drugs to treat chronic musculoskeletal pain. was founded in 2020.

Karma Biotechnologies, Inc. develops therapies for autoimmune diseases. It offers Xavines, a therapeutic to treat autoimmunity, allergies, and food sensitivities. Karma Biotechnologies, Inc. was incorporated in 2019 and is based in Los Angeles, California.

Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.

Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

CyGenica specializes in developing innovative delivery solutions for drugs, gene editing components, and antibiotics using a non-viral, non-toxic platform. The company focuses on creating molecular devices that facilitate the programmable delivery of anticancer drugs and other therapeutic agents directly into cells. These devices are designed to cross cellular membrane barriers, allowing for the effective transport of functional molecules into the cytoplasm and various cellular organelles. By enabling pharmaceutical and biotechnology companies to develop new types of anticancer drugs with extended brand lifecycles, CyGenica aims to enhance the efficacy and safety of medical treatments.

Neurode makes non-invasive wearable devices that improve cognitive performance for people with neurological conditions. The company's wearable device, Neurode Wave, is a headset that is a drug-free treatment that uses non-invasive electrical stimulation to balance the underactivity present in ADHD brains. Using it in short daily sessions in combination with the company's paired app provides lasting improvements in symptoms like working memory, attention, and impulse control. The Neurode app is designed to be paired with the device. Paired activities are used in conjunction with the headset to improve performance in tasks requiring the use of executive functions. The app also works separately from the device as an all-in-one ADHD management plan. It has checklists and reminders for forgetful users, custom alarms developed by clinicians to help develop self-awareness, and trackers for a healthy diet and exercise. The company was founded in Sydney, New South Wales in 2021.

Oralta is a U.S.-based company that specializes in the manufacture of probiotic supplements aimed at improving oral health. Its flagship product, FRESH BREATH, consists of chewable tablets designed to combat bad breath by eliminating odor-causing bacteria while promoting the growth of beneficial probiotic strains. The tablets work by preventing the buildup of harmful germs, reducing their growth, and inactivating the byproducts responsible for unpleasant odors. Oralta's innovative approach focuses on restoring a healthy balance of oral bacteria, ultimately enhancing overall oral hygiene and addressing conditions such as tooth decay and gum disease.

Ria Health is a telehealth provider focused on treating alcohol use disorders through a mobile platform. Founded in 2013 and based in San Francisco, California, the company connects users with addiction specialists for personalized support and guidance. Ria Health employs evidence-based protocols, including medication-assisted treatment, harm reduction, and cognitive behavioral therapy, to assist heavy drinkers seeking to reduce or stop their alcohol consumption. The Ria app facilitates secure, HIPAA-compliant interactions, allowing for video and phone consultations, breathalyzer measurements, and progress tracking. By offering a private and convenient treatment option, Ria Health aims to address the significant gap in care for individuals struggling with alcohol-related issues, ensuring effective and affordable support that aligns with payer objectives.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

KOLIBRI is an early-stage deep-tech biotech start-up company that unlocks the potential of gene therapies and next-generation vaccines. It aims to make large-scale viral vector manufacturing cheaper and faster by combining cutting-edge techniques in chemical optimization and acoustics. The company was founded n 2020.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

Developer of a portable neuroimaging system designed to track and predict recovery of movement function during the rehabilitation of hemiparesis. The company's systems utilize a proprietary optical imaging system, assessment software, and data analytics to measure neural biomarkers and aid neurological rehabilitation, enabling therapists to make sustainable treatment decisions.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.

Synthetix is a decentralized synthetic asset issuance protocol operating on the Ethereum blockchain, designed for derivatives trading within the decentralized finance (DeFi) space. Based in Sydney, Australia, the platform enables the creation of on-chain synthetic assets and digital tokens. Synthetix offers various products, including the Synthetix Network Token (SNX), which serves as collateral for synthetic assets like sUSD and sEUR. Additionally, it provides Mintr, a decentralized application for SNX holders, and Swappr, a tool facilitating conversions between SNX and Ethereum. The platform aims to address the challenges of volatility in cryptocurrencies by allowing users to gain exposure to real-world currencies, commodities, and indices through synthetic assets, thereby ensuring liquidity and enabling peer-to-contract trading. Founded in 2018, Synthetix promotes an open and transparent ecosystem, leveraging smart contracts to enhance trading efficiency and accessibility.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

Arthronica Ltd is a London-based company that develops an artificial intelligence platform focused on patient monitoring and rehabilitation. Founded in 2018, the company specializes in solutions such as skeletal tracking, visual strength assessment, image analysis, and video analysis. Its innovative technology aims to validate algorithms capable of monitoring and predicting key disease activities in chronic rheumatic conditions. Currently, Arthronica is engaged in clinical trials in both the United Kingdom and the United States, further advancing its research and application in the medical field.

Lief Therapeutics specializes in developing a discreet bio-sensing patch designed to measure heart rate and breathing patterns. The company's flagship product, a wearable device, allows users to manage their natural stress response through biofeedback exercises, helping them to monitor and control their behaviors, emotions, and thoughts in real-time. This device not only aids individuals in recognizing stress and anxiety patterns but also enables clinicians to track patient progress, conduct training sessions, and manage psychological assessments. Additionally, Lief Therapeutics offers the Lief Health Score application, which facilitates the recording of thoughts, emotions, and sensations, enabling users to track their daily progress and engage in targeted exercises. Founded in 2014, the company is headquartered in San Francisco, California, and sells its products online.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Bravrr's first product, BruxRelief, is poised to disrupt the over $9B market of bruxism (unconscious teeth grinding) disorder. 1 in 3 people suffer from bruxism disorder, but sadly less than 10% are diagnosed or ever receive treatment. Worse yet, many patient only receive treatment after damage to their teeth has already occurred or they've developed severe jaw / neck pain, headaches, migraines, TMJ or tinnitus. The diagnostic devices that are on the market are vastly too complex and costly. Bravrr's BruxRelief wearable is an easy to use wearable headband that connects to your smartphone and provides analysis of your nightly bruxism behavior and sleeping patterns through and intuitively built app.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Valanx Biotech GmbH, founded in 2017 and based in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company focuses on creating SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with therapeutic agents to produce antibody-drug conjugates for cancer treatment. This technology also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Valanx Biotech offers bioanalytics and mass spectrometry services to meet specific client needs, enhancing the efficiency and effectiveness of protein-drug conjugate development.

Metabolomic Diagnostics Ltd. is a medical diagnostics company based in Little Island, Ireland, specializing in the early detection of pregnancy-related complications through innovative biomarker-based diagnostic solutions. Founded in 2011, the company has developed a mass spectrometry-based platform capable of analyzing multiple biomarkers simultaneously. This technology facilitates the predictive diagnosis of pre-eclampsia, a serious condition characterized by high blood pressure and proteinuria during pregnancy. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve personalized care for pregnant women. The company's vision includes enhancing clinical decision-making and prenatal care by providing accurate risk assessments for complications such as gestational diabetes and preterm birth. Through collaboration with prenatal care providers, Metabolomic Diagnostics seeks to empower clinicians and pregnant women alike, ultimately aiming to improve pregnancy outcomes on a global scale.

Convalesce Inc. is a therapeutic company focused on developing stem cell-based therapies for neurodegenerative conditions, including Parkinson's disease. Founded in 2018 and headquartered in San Francisco, California, the company utilizes advanced biomaterials to enhance its treatment approaches. Convalesce aims to address the degeneration of neurons associated with various neurological disorders through innovative therapeutic solutions.

renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

Valanx Biotech GmbH, founded in 2017 and based in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company focuses on creating SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with therapeutic agents to produce antibody-drug conjugates for cancer treatment. This technology also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Valanx Biotech offers bioanalytics and mass spectrometry services to meet specific client needs, enhancing the efficiency and effectiveness of protein-drug conjugate development.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Zennea Technologies develops therapeutic wearable that reduces snoring and improve health through sleep. The company is based in Surrey, Canada.